30 results about "Abnormal liver function" patented technology

The invention relates to a non-invasive apparatus system for monitoring drug hepatotoxicity, and its uses in monitoring drug-induced hepatotoxicity and abnormal liver function.

The invention relates to the technical field of medicines, in particular to a compound monoammonium glycyrrhizate S injection pharmaceutical composition as well as a preparation method and applicationthereof. The pharmaceutical composition is prepared from 400-600g of monoammonium glycyrrhizinate S, 300-500g of cysteine hydrochloride, 4.0-6.0kg of glycine, 400-650g of anhydrous sodium sulfite, 40-60g of disodium edetate, 1.0-3.0kg of sodium chloride and 100-200g of activated carbon; finally, fixing the volume to 180-450L by using water for injection. The preparation method of the pharmaceutical composition comprises the steps of weighing, concentrating, diluting, carrying out sterile filtration, filling and sealing. The compound monoammonium glycyrrhizate S injection pharmaceutical composition can be used for treatment of abnormal liver function caused by acute and chronic and persistent hepatitis, not only improves medicament stability, but also can avoid insoluble particles from generating in medicament, and is good in safety, better in efficacy and more remarkable in curative effect.

A Chinese traditional medicine used for curing the disease of severe pregnant vomiting and abnormal liver function belongs to the Chinese traditional medicine for curing pregnant vomiting. The ingredients of the medicine (with weights) contain calcined abalone shell 24g, trichosanthes seed 12g, parched white peony root 10g, angelica body 10g, mulberry leaf 12g, phragmites japonica 12g, perilla leaf 6g, perilla stem 6g, flower bud of Japanese apricot 5g, ginger pinellia 9g and raw and roasted liquorice 5g; the auxiliary ingredients contain nobile dendrobium 12g and lilyturf root 10g under a situation of quenching and thirst; heterophylly falsestarwort root 12g under the situation of deficiency of qi and being too lazy to speak; magnolia obavata 6g under the situation of thick greasy tongue coating; American ginseng 2g under the situation of red tongue and little coating; ramie root 24g, Chinese taxillus herb 15g and lotus rhizome knot 20g under the situation of waist soreness, bellyache and colporrhagia. The composition of the Chinese herbal medicine is simple and the medicines used in the prescription are all natural herbs; the fetching and use are convenient and the manufacture method is simple; the medicine effect is excellent and the price is low; in this way, the herbal medicine is especially fit for people living in remote villages far away from counties and towns; the curing expense for patients with the serious disease of pregnant vomiting and abnormal liver function is low which solves the problem that the household income is low and the life is poor and the medical conditions is deficient locally.

The invention aims at providing a prescription for treating hepatitis. The prescription comprises the following components: 12 grams of angelica sinensis, 12 grams of radix rubiae, 12 grams of radix bupleuri, 12 grams of lumbricus, 10 grams of radix paeoniae rubrathe, 12 grams of cattail pollen, 10 grams of immature bitter oranges, 12 grams of trogopterus dung, 10 grams of turtle shells, 12 grams of endothelium corneum gigeriae galli, 10 grams of pericarpium citri reticulatae viride, 20 grams of pork livers and 20 grams of couchgrass roots. The prescription provided by the invention puts an emphasis on liver protection, has an outstanding curative effect and is suitable for the treatment of multiple hepatitis symptoms, such as chronic hepatitis, early-phase hepatocirrhosis, banti syndrome, hepatalgia, abdominal fullness and distention, abnormal liver function, hyperhepatia, and the like.

The invention relates to a traditional Chinese medicine for treating alcoholic liver injury. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 30-90 parts of radix puerariae, 20-60 parts of pueraria flowers, 20-50 parts of polygonum cuspidatum, 15-30 parts of capillary Artemisia, 15-30 parts of codonopsis pilosula, 15-30 parts of white atractylodes rhizome, 20-50 parts of salvia miltiorrhiza, 10-20 parts of loofah sponge, 15-30 parts of fructus lycii, 15-30 parts of fructus corni, 10-15 parts of fructus amomi, 15-20 parts of amomum cardamomum, 15-30 parts of rhizoma alismatis, 15-30 parts of poria cocos, 10-20 parts of pericarpium citri reticulatae and 15-30 parts of medicated leaven. According to the traditional Chinese medicine, pure traditional Chinese medicines are adopted, and pills are adopted as dosage forms; the traditional Chinese medicine is taken by white boiled water, and the alcoholic liver injuries, such as abnormal liver function and fatty liver change, can be effectively treated. The adopted traditional Chinese medicines are reasonable in composition of prescription, and the treating effect is obvious. No obvious toxic and side effects are caused, the price is low, and the treatment compliance is good.

The invention relates to novel application of massoia lactone and 5-hydroxy-2-caproleic acid. An animal model test proves that for a CCL4 induced mouse hepatic fibrosis and liver cirrhosis model, after massoia lactone or 5-hydroxy-2-caproleic acid is used for intervention, the abnormal liver function can be remarkably improved, the serum aspartate amino transferase, glutamic-pyruvic transaminase and the total bilirubin level are lowered, the content of hepatic tissue hydroxyproline is decreased, hepatic stellate cell activation is inhibited, the type I collagen expression is reduced, and liver tissue collagen deposition is restrained; for a HepG-2 nude-mouse transplanted tumor model, after massoia lactone or 5-hydroxy-2-caproleic acid is used for intervention, increase of the weight and size of transplantation tumors can be remarkably inhibited. Accordingly, the two compounds can be used for preparing liver fibrosis, liver cirrhosis and liver cancer resistance drugs.

The invention relates to the technical field of medicines and specifically relates to a compound ammonium glycyrrhetate S injection pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition is prepared from monoammonium glycyrrhizinate S, cysteine hydrochloride, glycine, anhydrous sodium sulfite, edetate disodium, sodium chloride, sodium citrate, citric acid and traditional Chinese medicine extract; finally, the volume is fixed at 180-450L with injection water; the pharmaceutical composition is prepared by the following steps: weighing and grinding, reflux extraction, mixing and dosing, sterilization and filtration and filling and sealing; the pharmaceutical composition can be applied to the treatment of abnormal liver function caused by acute and chronic persistent hepatitis; according to the compound ammonium glycyrrhetate S injection pharmaceutical composition provided by the invention, the treatment effect and stability of the drug are enhanced while the solubility of particles in the drug is higher; thus, the injection pharmaceutical composition has higher safety and better effect, the dosage is reduced, and the medication safety is improved for the patients.

The invention belongs to the field of medicines, and particularly relates to a chitosan oligosaccharide enteric-coated dropping pill and application thereof in preparation of a medicine for treating non-alcoholic fatty liver disease. The chitosan oligosaccharide enteric-coated dropping pill provided by the invention consists of an enteric-coated layer coating and a pill core in a mass ratio of (6-10): (13-17). The chitosan oligosaccharide enteric-coated dropping pill provided by the invention can improve the hyperglycemia level of an organism and abnormal lipid metabolism caused by high-fat and high-sucrose diet, improve abnormal liver function indexes caused by the high-fat and high-sucrose diet to a certain extent, enhance the serum antioxidant function of a mouse with the non-alcoholic fatty liver disease, promote release of anti-inflammatory factors and improve the anti-inflammatory effect of the mouse with the non-alcoholic fatty liver disease. The purpose of relieving inflammation is achieved, the stability of the chitosan oligosaccharide is enhanced, and the roundness of the chitosan oligosaccharide enteric-coated dropping pill is good.

The invention relates to application of Parabacteroides distasonis in the prevention or treatment of obesity or related diseases thereof. The Parabacteroides distasonis can effectively relieve the obesity and related diseases such as hyperlipidemia, diabetes, abnormal liver function and abnormal intestinal microecology, can increase the abundance of intestinal beneficial microbial flora and applicable to drugs, food or healthcare products for preventing and treating the obesity and related diseases.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating abnormal liver function. The traditional Chinese medicine composition consists of the following medicines such as ginseng, rhizoma polygonati, rhizoma atractylodis, radix sophorae flavescentis, poria cocos, radix ophiopogonis, radix polygonum multiflorum preparata, rehmannia, dogwood, coptis chinensis and eupatorium. The experiment proves that the medicine can effectively treat the abnormal liver function.

The invention discloses an anti-HBV traditional Chinese medicine formula. The anti-HBV traditional Chinese medicine formula comprises the following raw materials: in parts by weight, 1-3 parts of Radix Pseudostellariae, 1-3 parts of Astragalus, 2-3 parts of Hedyotis diffusa, 2-3 parts of Hypericum japonicum, 2-3 parts of dandelion, 2-3 parts of schisandra chinensis, 2-5 parts of herba artemisiae scopariae, 2-4 parts of rhizoma sparganic, 2-3 parts of curcuma zedoaria, 2-3 parts of bupleurum, 2-4 parts of curcuma aromatica, 2-3 parts of fructus forsythiae, 1-3 parts of endothelium corneum gigeriae galli, 1-2 parts of Akebia trifoliata, 1-3 parts of fleece flower roots, 1-2 parts of fructus lycii, 1-2 parts of radix rehmanniae preparata, 1-3 parts of gardenia, 1-3 parts of rhizoma atractylodis, 1-2 parts of Sophora flavescens, 1-3 parts of radix sophorae tonkinensis, 1-2 parts of licorice, 1-3 parts of angelica sinensis, 1-3 parts of radix paeoniae alba, 1-2 parts of atractylodes, 1-3 parts of fructus aurantii, 1-3 parts of malt, 1-2 parts of maggot powder, 1-2 parts of Polygonum cuspidatum and 1-3 parts of Caulis Spatholobi. The invention also discloses a preparation method of granules and an oral liquid of the formula. Through the formula, the immune function of the patient body can be improved, the body produces antibodies, and the formula can be applied to treatment of hepatitis B virus, early and middle liver cancers, cirrhosis, hepatosplenomegaly and abnormal liver functions; and the formula has little irritation, no allergic reactions and a high cure rate.

The invention relates to an application of 5-hydroxy-2-decenoic acid in preparation of a drug for anti-liver fibrosis, chronic liver disease, liver cirrhosis and liver cancer. The animal model tests show that for CCL4-induced liver fibrosis and cirrhosis in mice, intervention with 5-hydroxy-2-decenoic acid can significantly improve abnormal liver function and reduce serum aspartate aminotransferase, glutamate pyruvate transaminase and total bilirubin levels, reduces liver tissue hydroxyproline content, inhibits liver stellate cell activation, reduces type I collagen expression, and inhibits liver tissue collagen deposition; and for a HepG-2 nude-mouse transplanted tumor model, the use of 5-hydroxy-2-decenoic acid significantly inhibites the growth of the weight and volume of the transplanted tumor. Therefore, the 5-hydroxy-2-decenoic acid can be used for the preparation of the drug for anti-liver fibrosis, chronic liver disease, liver cirrhosis and liver cancer.

A Chinese medicine for treating hepatitis B, hepatofibrosis, hepatosplenomegaly, hepatocirrhosis, and abnormal liver function is prepared from 5 Chinese-medicinal materials including ginseng, ganoderma, radical lobelia, eclipta, etc.

The present disclosure relates to a herbal compound extract to moderate diabetes with liver necrosis and fibrosis and applications thereof wherein a herbal compound consists of 10 to 20 units rhizome of Dendrobium nobile Lindl, 6 to 12 units fruiting body of Antrodia camphorata, 12 to 20 units root of Panax ginseng C. A. Mey, 10 to 30 units root of Rehmannia glutinosa Libosch, 15 to 30 units rhizome of Salvia miltiorrhiza Bge., 6 to 12 units all of Pheretima asperfillm (E. Perrier), 10 to 30 units root of Pueraria mirifica, 8 to 15 units fruit of Schisandra chinensis (Turcz.) Baill and 6 to 8 units rhizome of Glycyrrhiza uralensis Fisch and the herbal compound extract is able to moderate symptoms comprising hyperglycemia, hyperlipidemia, abnormal liver function about liver necrosis and fibrosis due to the diabetes.

The invention relates to a traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression. The traditional Chinese medicine has obvious treatment effects on symptoms such as deprementia, chest hypochondriac pain, lassitude, upset irritability, abdominal distension and diarrhea and the like of the liver constraint and spleen deficiency type post-strokedepression, improves spirit and emotions, promotes the recovery of neural functions of stroke patients, and does not have obvious toxic or side effects such as dizziness, hypodynamia, somnolence, drymouth, constipation, hypotension, abnormal liver functions, epilepsy, cardiac arrhythmia, toxicosis and the like. The technical scheme is that: the traditional Chinese medicine is prepared form the following raw materials by weight: 10 to 14g of bupleurum, 9 to 11g of turmeric root-tuber, 10 to 14g of Chinese angelica, 10 to 14g of white paeony root, 13.5 to 16.5g of fried largehead atractylodes rhizome, 9 to 11g of Indian buead, 18 to 22g of codonopsis pilosula, 9 to 11g of tangerine peel, 9 to 11g of bamboo shavings, 13.5 to 16.5g of gardenia, 4.5 to 5.5g of mint and 2.7 to 3.3g of liquoricroot. The traditional Chinese medicine is prepared into decoction by the conventional soaking, decocting and filtering or is prepared by directly blending market-sold single Chinese medicinal formulaparticles. The traditional Chinese medicine has the advantages of high reliability, high safety, high flexibility, no dependence and the like.

The invention relates to a non-invasive apparatus system for monitoring drug hepatotoxicity, and its uses in monitoring drug-induced hepatotoxicity and abnormal liver function.

The invention discloses the application of a traditional Chinese medicine composition in the preparation of medicine for treating abnormal liver function. The traditional Chinese medicine composition is composed of ginseng, sealwort, atractylodes rhizome, flavescens, poria cocos, radix radix radix Radix Polygoni Multiflori, rehmannia glutinosa, cornel officinalis, berberine, perrin and the like. Experiments have proved that the medicine of the invention can effectively treat abnormal liver function.

The invention discloses an application of ginsenoside CK and Rh1 and a composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance, and relates to a medical application of the ginsenoside CK and Rh1 and the composition thereof. According to the application, in-vitro and in-vivo studies show that the ginsenoside CK and Rh1 and the composition thereof can regulate and control synthesis and degradation of epimatrix of hepatic stellate cells (HSC-T6) of mice, significantly improve the abnormal liver function, lipid metabolism disorders, abnormal glucose metabolism and hepatic fibrosis degree of the non-alcoholic fatty hepatic fibrosis mice, and has a development prospect for serving as the medicine of combination of non-alcoholic fatty hepatic fibrosis and insulin resistance.

The invention provides a pharmaceutical composition for treating pulmonary tuberculosis, which comprises a main drug and an auxiliary drug, and the main drug comprises rifapentine and glucurolactone. The main drugs comprise the following components in parts by weight: 0.5-5 parts of rifapentine and 0.5-10 parts of glucurolactone, and the weight ratio of the rifapentine to the glucurolactone is (0.375-0.75): 1. According to the pharmaceutical composition for treating pulmonary tuberculosis disclosed by the invention, the rifapentine and the glucurolactone are prepared into the pharmaceutical composition according to a reasonable proportion, so that the abnormal liver function rate of a patient is reduced.

The invention relates to a traditional Chinese medicine composition for curing chronic hepatitis. The traditional Chinese medicine composition adopts more than 10 traditional Chinese herbs as raw materials, such as radix astragali, red sage roots, achyranthes roots, and the like and has the efficacies of promoting blood circulation, removing blood stasis, clearing residual toxicity, soothing liver-qi stagnation, nourishing yin and liver, eliminating stagnation, and the like. The invention can cure the chronic hepatitis and the symptoms of hepatopaths with abnormal liver functions, such as dark face, somasthenia, malabsorption and neurolysis and has the advantages of simple manufacture method, accurate therapeutic effect, safety, no toxic side effect, convenient taking, low cost, and the like.

The invention discloses a processing and extracting method for preparing a sobering-up preparation from traditional Chinese medicinal materials, which comprises the following steps: white paeony root,cassia twig, oriental waterplantain rhizome, chrysanthemum, tuckahoe, freeze-dried fructose powder, aluminum phosphate gel, corn stigma, coix seed, corn oligopeptide powder, parthenocissus tricuspidata, hovenia dulcis thunb and glossy privet fruit. The traditional Chinese medicinal preparation is remarkable in sobering up the drunk. The drinking amount can be increased by taking the preparation before drinking liquor, and the sobering-up effect can be quickly promoted by taking the preparation after drinking liquor. The traditional Chinese medicine tea can nourish the liver, protect the stomach and induce diuresis, is suitable for people with alcohol allergy, easy fatigue, abnormal liver functions (such as fatty liver and alcoholic liver), fatigue driving and sweet dumpling passing work,takes effect quickly and does not have toxic or side effect.

The invention discloses a traditional Chinese medicine for regulating the liver function. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 1 to 5g of radix bupleuri, 3 to 7g of eucommia ulmoides, 8 to 12g of astragalus membranaceus, 8 to 12g of rhizoma atractylodis macrocephalae, and 1 to 5g of fructus jujubae. When the traditional Chinese medicine is prepared, 1,400 to 1,600g water is added to all medicines and then decocted with slow fire until reaching one third of the water, then 480 to 520g table vinegar is added for later use; in addition, gall bladder (processed) of pig, honey, and corn stigma or / and catkin are further added. The traditional Chinese medicine for regulating liver function has the beneficial effects that the prepared soup for regulating liver, nourishing spleen and tonifying kidney is able to treat abnormal liver function caused by hepatitis, liver cirrhosis, liver ascites, liver cancer and the like; the repeated clinical practices prove that the traditional Chinese medicine has the advantages of being obvious in effect, small in dosage, convenient to take, quick to enable all effects to focus on one position, long in effect duration, relatively high in recovery rate and relatively low in cost.

The invention relates to novel application of known compound coniferyl ferulate, and belongs to the technical field of medicines. Completed animal model tests indicate that the abnormal liver function of a CC14 induced mouse liver fibrosis model can be remarkably improved after coniferyl ferulate intervenes, the serum aspartate amino transferase and the level of serum total bilirubin can be reduced, the content of hydroxyproline can be reduced, the activation of hepatic stellate cells can be inhibited, type I collagen expression can be reduced, and collagen deposition of hepatic tissues can be inhibited.

The invention belongs to the field of treatment of hepatitis B and particularly relates to traditional Chinese medicine composition for treating chronic hepatitis B. The traditional Chinese medicine composition is prepared from Chinese herbal medicines by weight as follows: 27-32 g of herba commelinae, 0.8-1.2 g of toad skin, 9-13 g of radix astragali, 15-20 g of herba artemisiae scopariae, 5-8 gof radix glycyrrhizae, 15-17 g of radix isatidis and 14-17 g of spreading hedyotis herb. The provided traditional Chinese medicine composition for treating chronic hepatitis B has the efficacy of strengthening the body resistance, removing toxins, dispersing the liver, rectifying qi, removing dampness, reducing swelling and resolving mass and the like, has the functions of regulating and activating a body immunity system and clearing away HBV (hepatitis B virus), protects the liver and promotes recovery of liver cells. After the traditional Chinese medicine composition is taken for 1-3 coursesof treatment according to the technology, the antigen titer of the surface of the HBV is reduced by 1-3 times, the treatment efficacy is remarkable after patients with the HBV and abnormal liver function take the composition within half a year, and the hepatitis virus is basically removed. The traditional Chinese medicine composition has a remarkable effect when used for treating hepatitis B, islow in cost and is applicable to hepatitis B patients and HBV carriers.

The invention provides a medicinal preparation with alcohol effect expelling and liver protection functions and a preparation method of the medicinal preparation and belongs to the technical field oftraditional Chinese medicines. The medicinal preparation with the alcohol effect expelling and liver protection functions is made of the following raw materials in parts by weight: 10-20 parts of white plum blossoms, 10-20 parts of akebiaquinata, 9-17 parts of loofah sponge, 8-15 parts of dalbergia balansae, 8-15 parts of jasminum elongatum, 6-12 parts of olive shells, 6-12 parts of spreading violet, 3-10 parts of silkworm excrement, 3-10 parts of a mixture of wheat flour, wheat bran and multiple medicines, 3-10 parts of panicum repens and 3-10 parts of bothrocaryum controversum. The medicinalpreparation provided by the invention has the effects of clearing livers and harmonizing stomachs as well as drying damp and expelling alcohol effects, is applicable to patients who can only endure alow alcohol dose, take a great amount of wine with high alcoholic strength and have alcoholic hepatitis, and is capable of remarkably relieving or eliminating multiple uncomfortable symptoms such asright rib pain, anorexia and gastral cavity pain, nausea and vomiting, red faces, mouth thirst and bitterness, yellow and smell urea, eye and body jaundice, red tongues, yellow and thick tongue coating, rapid blood pulse, swelling livers, haphalgesia and abnormal liver functions, of the patients after excessive alcohol taking.

The invention relates to the technical field of application of prevention and treatment medicines, in particular to an application of urine-derived stem cells in preparation of a biological agent and a medicine for treating non-alcoholic fatty liver disease, losing weight and lowering lipid. The urine-derived stem cells are used for preparing non-alcoholic fatty liver treatment injections, infusion solutions or other pharmaceutical preparations containing the urine-derived stem cells. Experimental results show that the urine-derived stem cells (USCs) can significantly inhibit formation of high fat-induced NAFLD. It is found that USCs can significantly inhibit lipid deposition in the liver of an HFD mouse; the USCs can significantly relieve glucose tolerance and insulin resistance of HFD mice. NAFLD is a problem which increasingly affects human health; particularly, NAFLD is a common abnormal liver function troubling the health of the elderly; in addition, the USCs are obtained from a patient, so that side effects caused by allogenic stem cell treatment can be effectively avoided, and the USCs have a relatively good prospect when being used for treating the NAFLD.

The invention discloses a ginsenoside composition capable of preventing and treating alcoholic fatty liver. The pharmaceutical composition of the present invention that can be used for the prevention and / or treatment of alcoholic fatty liver comprises a preventive and / or therapeutic effective amount of ginsenoside Rk3 and ginsenoside Rh4 as active ingredients, and a pharmaceutically acceptable carrier, the pharmaceutical composition wherein, the weight ratio of ginsenoside Rk3 to ginsenoside Rh4 is 1:0.5-2, preferably 1:0.9-1.1. The ginsenoside composition of the invention can obviously improve the abnormal liver function index caused by heavy drinking, and reduce the inflammatory infiltration of liver tissue and the generation of fat vacuoles. The present invention provides a synergistic pharmaceutical composition comprising ginsenosides Rk3 and Rh4, capable of preventing and / or treating alcoholic fatty liver.

The invention discloses a bio-medicine for liver diseases, a medical food for liver diseases, a preparation method of the bio-medicine for liver diseases and a preparation method of the medical food for liver diseases. The bio-medicine is prepared from the following raw materials in parts by weight by partlycrushing, partlyextracting active ingredients or mixing after enzyme digestion: 20-40 partsof radix astragali, 0.7-15 parts of Eupolyphaga Seu Steleophaga, 1-20 parts of cordyceps sinensis (or an artificial culture thereof), 2-10 parts of immature bitter orange, 10-16 parts of radix salviae miltiorrhizae and 10-20 parts of red peony root; the bio-medicine or medical food of the invention is used for the treatment and / or auxiliary treatment of liver diseases such as chronic, active hepatitis, liver cirrhosis, abnormal liver functions and the like, and has the advantages of definite curative effects, small side effects and low treatment cost compared with other treatment methods. Inaddition, there are few restrictive requirements on patients in the treatment process and the normal work and life of patients are not affected.

The invention provides applications of pegylated artesunate shown as the formula (I) in preparing medicines capable of resisting hepatic pathological changes. According to the applications, pegylated artesunate can obviously reduce the hepatic fibrosis condition and abnormal liver function of hepatic fibrosis rats caused by carbon tetrachloride, reduce the amount of the serum fibrosis markers such as hyaluronidase (HA), laminin (LN) and procollagen III (PC-III), reduce the amount of alamine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum, reduce the contents of malondialdehyde (MDA) and hydroxyproline (Hyp) of the liver tissue, and effectively prevent the development of liver fibrosis and promote the reversion of liver fibrosis, and has the significant differences compared with artesunate under the same dosage. In addition, the pegylated artesunate is good in water solubility, high in bioavailability, and long in half-life period, and the administration times can be reduced. The formula (I) is shown as follows.

The invention belongs to the technical field of medicine combination, and particularly relates to a combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of a medicine for treating megaloblastic liver cancer. The combined medicine composition for treating megaloblastic liver cancer comprises thymalfasin, vitamin C, an anti-PD-1 antibody, apatinib and tegafur. The invention provides the combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of the medicine for treating megaloblastic liver cancer. On the premise of not carrying out TACE operation and conventional radiotherapy and chemotherapy, the volume of the tumor at the liver is effectively reduced, the growth of the liver tumor can be obviously inhibited, the illness state of the patient is relieved, even the intrahepatic metastasis, the serum thymidine kinase content and the alpha fetoprotein content are reversed to be restored to a normal range, and abnormal liver function and bone marrow function, toxic and side effects and adverse events are not caused.